Eric Fain Buys 20,000 Shares of Orchestra BioMed (NASDAQ:OBIO) Stock

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Director Eric Fain acquired 20,000 shares of the company’s stock in a transaction dated Thursday, May 14th. The stock was acquired at an average price of $4.13 per share, for a total transaction of $82,600.00. Following the completion of the purchase, the director directly owned 91,709 shares of the company’s stock, valued at $378,758.17. This trade represents a 27.89% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Orchestra BioMed Price Performance

NASDAQ OBIO opened at $4.00 on Wednesday. The stock has a 50-day simple moving average of $4.27 and a 200 day simple moving average of $4.27. Orchestra BioMed Holdings, Inc. has a twelve month low of $2.20 and a twelve month high of $5.42. The stock has a market capitalization of $239.52 million, a PE ratio of -4.12 and a beta of 0.52. The company has a debt-to-equity ratio of 0.35, a quick ratio of 7.01 and a current ratio of 7.03.

Orchestra BioMed (NASDAQ:OBIO) last released its earnings results on Tuesday, May 12th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.07. Orchestra BioMed had a negative return on equity of 157.46% and a negative net margin of 166.96%.The firm had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.92 million. Research analysts anticipate that Orchestra BioMed Holdings, Inc. will post -1.54 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Weiss Ratings cut shares of Orchestra BioMed from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, April 21st. B. Riley Financial dropped their price objective on shares of Orchestra BioMed from $12.00 to $10.00 and set a “buy” rating on the stock in a report on Tuesday. Barclays upped their price objective on shares of Orchestra BioMed from $12.00 to $13.00 and gave the company an “overweight” rating in a research report on Wednesday, May 13th. Chardan Capital reissued a “buy” rating and set a $20.00 target price on shares of Orchestra BioMed in a research report on Thursday, March 12th. Finally, Wall Street Zen lowered Orchestra BioMed from a “hold” rating to a “sell” rating in a research note on Saturday. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $13.60.

Orchestra BioMed News Summary

Here are the key news stories impacting Orchestra BioMed this week:

• Positive Sentiment: Director Eric Fain bought 20,000 shares, and insider David P. Hochman bought 5,000 shares, signaling management confidence in Orchestra BioMed’s outlook. SEC filing for Eric Fain purchase
• Positive Sentiment: HC Wainwright reiterated a Buy rating and $10 price target, while also raising some near- and medium-term earnings estimates, which can reassure investors about the company’s trajectory. MarketBeat OBIO coverage
• Positive Sentiment: Orchestra BioMed announced it will participate in the Jefferies Global Healthcare Conference, giving the company a near-term catalyst for investor attention and potential business updates. Jefferies conference announcement
• Neutral Sentiment: B. Riley Financial lowered its price target from $12 to $10, but kept a Buy rating, so the note was still constructive despite a reduced valuation view. Benzinga report
• Neutral Sentiment: The company’s latest earnings were mixed: it beat EPS expectations, but revenue came in below estimates, leaving investors focused on future pipeline progress rather than current sales. MarketBeat earnings coverage

Institutional Investors Weigh In On Orchestra BioMed

Several institutional investors and hedge funds have recently bought and sold shares of OBIO. Alyeska Investment Group L.P. acquired a new position in shares of Orchestra BioMed in the 3rd quarter valued at $3,386,000. Pathstone Holdings LLC acquired a new stake in shares of Orchestra BioMed during the 3rd quarter valued at about $2,495,000. Vanguard Group Inc. increased its stake in Orchestra BioMed by 28.0% in the third quarter. Vanguard Group Inc. now owns 1,481,875 shares of the company’s stock valued at $3,675,000 after acquiring an additional 324,558 shares during the period. Simplify Asset Management Inc. bought a new stake in Orchestra BioMed in the first quarter valued at about $932,000. Finally, 683 Capital Management LLC acquired a new position in Orchestra BioMed in the fourth quarter worth about $847,000. Institutional investors own 53.20% of the company’s stock.

About Orchestra BioMed

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.